Přístupnostní navigace
E-application
Search Search Close
Publication detail
HADDAD, Y. REMEŠ, M. ADAM, V. HEGER, Z.
Original Title
Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
Type
journal article in Web of Science
Language
English
Original Abstract
Most of the available crystal structures of epidermal growth factor receptor (EGFR) kinase domain, bound to drug inhibitors, originated from ligand-based drug design studies. Here, we used variations in 110 crystal structures to assemble eight distinct families highlighting the C-helix orientation in the N-lobe of the EGFR kinase domain. The families shared similar mutational profiles and similarity in the ligand R-groups (chemical composition, geometry, and charge) facing the C-helix, mutation sites, and DFG domain. For structure-based drug design, we recommend a systematic decision-making process for choice of template, guided by appropriate pairwise fitting and clustering before the molecular docking step. Alternatively, the binding site shape/volume can be used to filter and select the compound libraries.
Keywords
Structure-Based Drug Design; epidermal growth factor receptor (EGFR); kinase domain; molecular docking
Authors
HADDAD, Y.; REMEŠ, M.; ADAM, V.; HEGER, Z.
Released
28. 2. 2021
ISBN
1359-6446
Periodical
DRUG DISCOVERY TODAY
Year of study
26
Number
2
State
United Kingdom of Great Britain and Northern Ireland
Pages from
289
Pages to
295
Pages count
7
URL
https://www.sciencedirect.com/science/article/pii/S1359644620304220
BibTex
@article{BUT170589, author="Yazan Abdulmajeed Eyadh {Haddad} and Marek {Remeš} and Vojtěch {Adam} and Zbyněk {Heger}", title="Toward structure-based drug design against the epidermal growth factor receptor (EGFR)", journal="DRUG DISCOVERY TODAY", year="2021", volume="26", number="2", pages="289--295", doi="10.1016/j.drudis.2020.10.007", issn="1359-6446", url="https://www.sciencedirect.com/science/article/pii/S1359644620304220" }